Drugs Archives – Page 3 of 6 – Treatment Action Group

Landmark TB Trials Results Published in New England Journal of Medicine

May 6, 2021
Dorrit Walsh

Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.

Finally—A New Four-Month Treatment for Drug-Susceptible TB!

October 21, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.

Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos

October 21, 2020
Dorrit Walsh

El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

September 18, 2020
Dorrit Walsh

Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

Global Health and Human Rights Organizations Say U.S. Withdrawal from WHO Is Reckless Act That Could Delay Americans’ Access to COVID-19 Solutions and Prolong Global Pandemic

July 7, 2020
Dorrit Walsh

AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).

Treatment Action Group Statement on Bedaquiline Unaffordability

July 6, 2020
Dorrit Walsh

Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.

An Activist’s Guide to Rifapentine for the Treatment of TB Infection

April 30, 2020
Chad Cipiti

The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…

Science-Based Activism to End Epidemics, from AIDS to COVID-19

March 25, 2020
Dorrit Walsh

We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

March 3, 2020
Dorrit Walsh

Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.

Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia

January 22, 2020
Dorrit Walsh

Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.